eMedicine Specialties > Emergency Medicine > Obstetrics & Gynecology

Rh Incompatibility

Author: Leon Salem, MD, MS, Associate Attending Physician, Kaiser Permanente, Southern California
Coauthor(s): Karen R Singer, PA-C, Department of Pediatrics, Fountain Valley Medical Center, South Counties Pediatric Critical Care Medical Group, Fountain Valley and Long Beach, California
Contributor Information and Disclosures

Updated: Nov 4, 2009

Introduction

Background

The Rh factor (ie, Rhesus factor) is a red blood cell surface antigen that was named after the monkeys in which it was first discovered. Rh incompatibility, also known as Rh disease, is a condition that occurs when a woman with Rh-negative blood type is exposed to Rh-positive blood cells, leading to the development of Rh antibodies.

Rh incompatibility can occur by 2 main mechanisms. The most common type occurs when an Rh-negative pregnant mother is exposed to Rh-positive fetal red blood cells secondary to fetomaternal hemorrhage during the course of pregnancy from spontaneous or induced abortion, trauma,1 invasive obstetric procedures, or normal delivery. Rh incompatibility can also occur when an Rh-negative female receives an Rh-positive blood transfusion. In part, this is the reason that blood banks prefer using blood type "O negative" or "type O, Rh negative," as the universal donor type in emergency situations when there is no time to type and crossmatch blood.

The most common cause of Rh incompatibility is exposure from an Rh-negative mother by Rh-positive fetal blood during pregnancy or delivery. As a consequence, blood from the fetal circulation may leak into the maternal circulation, and, after a significant exposure, sensitization occurs leading to maternal antibody production against the foreign Rh antigen.

Once produced, maternal Rh immunoglobulin G (IgG) antibodies may cross freely from the placenta to the fetal circulation, where they form antigen-antibody complexes with Rh-positive fetal erythrocytes and eventually are destroyed, resulting in a fetal alloimmune-induced hemolytic anemia. Although the Rh blood group systems consist of several antigens (eg, D, C, c, E, e), the D antigen is the most immunogenic; therefore, it most commonly is involved in Rh incompatibility.

Recommendations for screening for Rh incompatibility are available from the US Preventive Services Task Force.2

Pathophysiology

The amount of fetal blood necessary to produce Rh incompatibility varies. In one study, less than 1 mL of Rh-positive blood was shown to sensitize volunteers with Rh-negative blood. Conversely, other studies have suggested that 30% of persons with Rh-negative blood never develop Rh incompatibility, even when challenged with large volumes of Rh-positive blood. Once sensitized, it takes approximately one month for Rh antibodies in the maternal circulation to equilibrate in the fetal circulation. In 90% of cases, sensitization occurs during delivery. Therefore, most firstborn infants with Rh-positive blood type are not affected because the short period from first exposure of Rh-positive fetal erythrocytes to the birth of the infant is insufficient to produce a significant maternal IgG antibody response.

The risk and severity of sensitization response increases with each subsequent pregnancy involving a fetus with Rh-positive blood. In women who are prone to Rh incompatibility, the second pregnancy with an Rh-positive fetus often produces a mildly anemic infant, whereas succeeding pregnancies produce more seriously affected infants who ultimately may die in utero from massive antibody-induced hemolytic anemia.

Risk of sensitization depends largely upon the following 3 factors:

  1. Volume of transplacental hemorrhage
  2. Extent of the maternal immune response
  3. Concurrent presence of ABO incompatibility

The incidence of Rh incompatibility in the Rh-negative mother who is also ABO incompatible is reduced dramatically to 1-2% and is believed to occur because the mother's serum contains antibodies against the ABO blood group of the fetus. The few fetal red blood cells that are mixed with the maternal circulation are destroyed before Rh sensitization can proceed to a significant extent. Fortunately, ABO incompatibility usually does not cause serious sequela.

Rh incompatibility is only of medical concern for females who are pregnant or plan to have children in the future. Rh-positive antibodies circulating in the bloodstream of an Rh-negative woman otherwise have no adverse effects.

Frequency

United States

Only 15% of the population lack the Rh erythrocyte surface antigen and are considered Rh-negative. The vast majority (85%) of individuals are considered Rh positive. Rh sensitization occurs in approximately 1 per 1000 births to women who are Rh negative. The Southwest United States has an incidence approximately 1.5 times the national average, which likely is caused by immigration factors and limited access to medical care since blood typing is a routine part of prenatal care. Even so, only 17% of pregnant women with Rh-negative blood who are exposed to Rh-positive fetal blood cells ever develop Rh antibodies.

Mortality/Morbidity

During the course of Rh incompatibility, the fetus is primarily affected. The binding of maternal Rh antibodies produced after sensitization with fetal Rh-positive erythrocytes results in fetal autoimmune hemolysis. As a consequence, large amounts of bilirubin are produced from the breakdown of fetal hemoglobin and are transferred via the placenta to the mother where they are subsequently conjugated and excreted by the mother. However, once delivered, low levels of glucuronyl transferase in the infant preclude the conjugation of large amounts of bilirubin and may result in dangerously elevated levels of serum bilirubin and severe jaundice.

  • Mildly affected infants may have little or no anemia and may exhibit only hyperbilirubinemia secondary to the continuing hemolytic effect of Rh antibodies that have crossed the placenta.
  • Moderately affected infants may have a combination of anemia and hyperbilirubinemia/jaundice.
  • In severe cases of fetal hyperbilirubinemia, kernicterus develops. Kernicterus is a neurologic syndrome caused by deposition of bilirubin into central nervous system tissues. Kernicterus usually occurs several days after delivery and is characterized by loss of the Moro (ie, startle) reflex, posturing, poor feeding, inactivity, a bulging fontanelle, a high-pitched shrill cry, and seizures. Infants who survive kernicterus may go on to develop hypotonia, hearing loss, and mental retardation.
  • Another serious life-threatening condition observed in infants affected by Rh incompatibility is erythroblastosis fetalis, which is characterized by severe hemolytic anemia and jaundice. The most severe form of erythroblastosis fetalis is hydrops fetalis, which is characterized by high output cardiac failure, edema, ascites, pericardial effusion, and extramedullary hematopoiesis. Newborns with hydrops fetalis are extremely pale with hematocrits usually less than 5. Hydrops fetalis often results in death of the infant shortly before or after delivery and requires an emergent exchange transfusion if there is to be any chance of infant survival.

Race

  • Approximately 15-20% of Caucasians, as opposed to 5-10% of African Americans, have the Rh-negative blood type.
  • Among individuals of Chinese and American Indian descent, the incidence of Rh-negative blood type is less than 5%.

Clinical

History

  • History of prior blood transfusion
  • Rh blood type of the mother
  • Rh blood type of the father (55% of Rh-positive men are genetically heterozygous for the Rh antigen and, therefore, produce Rh-negative offspring when mating with Rh-negative women 50% of the time.)
  • Previous pregnancies, including spontaneous and elective abortions
  • Previous administration of Rh IgG (RhoGAM)
  • Mechanism of injury in cases of maternal trauma during pregnancy
  • Presence of vaginal bleeding and/or amniotic discharge
  • Previous invasive obstetric procedures, such as amniocentesis, cordocentesis, chorionic villous sampling, or ectopic pregnancy
  • Note that a large fetal-maternal hemorrhage may occur without symptoms and with little or no evidence of trauma. Therefore, a high index of suspicion is warranted and a low threshold for treatment is indicated.

Physical

  • Evaluation of the vital signs and primary survey of the airway and cardiovascular system are indicated to ensure maternal stability.
  • A thorough pelvic examination is required.
  • In situations in which abdominal and/or pelvic trauma is a consideration, inspect for evidence of bruising that may suggest the possibility of significant fetomaternal hemorrhage.
  • When an infant with an Rh-negative mother is delivered in the emergency department, a thorough physical examination of the infant must be performed after initial stabilization, and a neonatal clinician must be consulted immediately.
  • Physical findings may vary from mild jaundice to extreme pallor and anemia with hydrops fetalis.

Causes

Factors that influence an Rh-negative pregnant female's chances of developing Rh incompatibility include the following:

  • Ectopic pregnancy
  • Placenta previa
  • Placental abruption
  • Abdominal/pelvic trauma
  • In utero fetal death
  • Any invasive obstetric procedure (eg, amniocentesis)
  • Lack of prenatal care
  • Spontaneous abortion

More on Rh Incompatibility

Overview: Rh Incompatibility
Differential Diagnoses & Workup: Rh Incompatibility
Treatment & Medication: Rh Incompatibility
Follow-up: Rh Incompatibility
References

References

  1. Thorp JM. Utilization of anti-RhD in the emergency department after blunt trauma. Obstet Gynecol Surv. Feb 2008;63(2):112-5. [Medline].

  2. [Guideline] US Preventive Services Task Force. Screening for Rh(D) incompatibility: recommendation statement. Rockville (MD): Agency for Healthcare Research and Quality (AHRQ). 2004;[Full Text].

  3. Herold TJ, Whittaker DS, Glynn T. Determining the accuracy of a rapid point-of-care test for determining Rh(D) phenotype. Acad Emerg Med. May 2005;12(5):474-6. [Medline].

  4. McMahan MJ, Donovan EF. The delivery room resuscitation of the hydropic neonate. Semin Perinatol. Dec 1995;19(6):474-82. [Medline].

  5. Agre P, Smith BL, Hartel-Schenk S. Biochemistry of the erythrocyte Rh polypeptides: a review. Yale J Biol Med. Sep-Oct 1990;63(5):461-7. [Medline].

  6. American College of Obstetricians and Gynecologists. Management of isoimmunization in pregnancy. ACOG Technical Bulletin 148; 1990.

  7. American College of Obstetricians and Gynecologists. Prevention of D isoimmunization. ACOG Technical Bulletin 147; 1990.

  8. Bowman JM. Hemolytic disease (erythroblastosis fetalis). In: Maternal-Fetal Medicine: Principles and Practice. 2nd ed. Philadelphia, Pa: WB Saunders; 1989:613-655.

  9. Copel JA, Gollin YG, Grannum PA. Alloimmune disorders and pregnancy. Semin Perinatol. Jun 1991;15(3):251-6. [Medline].

  10. Daffos F, Capella-Pavlovsky M, Forestier F. Fetal blood sampling via the umbilical cord using a needle guided by ultrasound. Report of 66 cases. Prenat Diagn. Oct 1983;3(4):271-7. [Medline].

  11. Grant J, Hyslop M. Underutilization of Rh prophylaxis in the emergency department: a retrospective survey. Ann Emerg Med. Feb 1992;21(2):181-3. [Medline].

  12. Issitt PD. Race-related red cell alloantibody problems. Br J Biomed Sci. Jun 1994;51(2):158-67. [Medline].

  13. Kleihauer E, Braun H, Betke K. Demonstation von fetalem Haemoglobin in den Erythrozyten eines Blutausstrichs. Klin Wochenschr. 1957;35:637-8.

  14. Mourant AE, Kopec AC, Domaniewska-Sobczak K. The Distribution of the Human Blood Groups and Other Biochemical Polymorphisms. 2nd ed. London, England: Oxford University Press; 1976.

  15. Peterec SM. Management of neonatal Rh disease. Clin Perinatol. Sep 1995;22(3):561-92. [Medline].

  16. Reece EA, Copel JA, Scioscia AL, Grannum PA, DeGennaro N, Hobbins JC. Diagnostic fetal umbilical blood sampling in the management of isoimmunization. Am J Obstet Gynecol. Nov 1988;159(5):1057-62. [Medline].

  17. Selinger M. Immunoprophylaxis for rhesus disease--expensive but worth it?. Br J Obstet Gynaecol. Jun 1991;98(6):509-12. [Medline].

  18. Walker RH. American Association of Blood Banks Technical Manual. 11th ed. Bethesda, Md: AABB; 1993.

Further Reading

Keywords

Rh incompatibility, rhesus factor, Rh disease, Rh factor, Rh-negative blood type, Rh-positive blood type, Rh antibodies, maternal Rh antibodies, Rh antigens, Rh sensitization, Rh blood group, Rh immunoglobulin G, Rh IgG, type O blood, O negative blood, Rh-positive fetal blood

Contributor Information and Disclosures

Author

Leon Salem, MD, MS, Associate Attending Physician, Kaiser Permanente, Southern California
Leon Salem, MD, MS is a member of the following medical societies: American College of Emergency Physicians
Disclosure: Nothing to disclose.

Coauthor(s)

Karen R Singer, PA-C, Department of Pediatrics, Fountain Valley Medical Center, South Counties Pediatric Critical Care Medical Group, Fountain Valley and Long Beach, California
Karen R Singer, PA-C is a member of the following medical societies: American Academy of Physician Assistants
Disclosure: Nothing to disclose.

Medical Editor

Assaad J Sayah, MD, Chief, Department of Emergency Medicine, Cambridge Health Alliance
Assaad J Sayah, MD is a member of the following medical societies: National Association of EMS Physicians
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Mark Zwanger, MD, MBA, Assistant Professor, Department of Emergency Medicine, Thomas Jefferson University
Mark Zwanger, MD, MBA is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, and American Medical Association
Disclosure: Medicines Company Consulting fee Consulting; Pfizer Salary Employment

CME Editor

John D Halamka, MD, MS, Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center
John D Halamka, MD, MS is a member of the following medical societies: American College of Emergency Physicians, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

Chief Editor

Pamela L Dyne, MD, Professor of Clinical Medicine/Emergency Medicine, David Geffen School of Medicine at UCLA; Attending Physician, Department of Emergency Medicine, Olive View-UCLA Medical Center
Pamela L Dyne, MD is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.